Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.71 |
| ▸ | CTSB | P07858 | 1/20 | 0.71 |
| ▸ | PSEN1 | P49768 | 8/20 | 0.60 |
| ▸ | PSEN2 | P49810 | 8/20 | 0.60 |
| ▸ | APH1B | Q8WW43 | 8/20 | 0.60 |
| ▸ | NCSTN | Q92542 | 8/20 | 0.60 |
| ▸ | APH1A | Q96BI3 | 8/20 | 0.60 |
| ▸ | PSENEN | Q9NZ42 | 8/20 | 0.60 |
| ▸ | CTSS | P25774 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | CTSD | P07339 | 3/20 | 0.57 |
| ▸ | REN | P00797 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26269169 | 1.00 | CTSK (0.71) | CTSKCTSBPSEN1PSEN2APH1B | |
| SCHEMBL8651650 | 1.00 | CTSK (0.71) | CTSKCTSBPSEN1PSEN2APH1B | |
| SCHEMBL29832567 | 0.92 | CTSK (0.61) | CTSKCTSBPSEN1PSEN2APH1B | |
| SCHEMBL29770339 | 0.92 | CTSK (0.61) | CTSKCTSBPSEN1PSEN2APH1B | |
| SCHEMBL8653583 | 0.91 | CTSK (0.71) | CTSKCTSBCTSSCTSL | |
| SCHEMBL7697656 | 0.90 | CTSS (0.60) | CTSKCTSBPSEN1PSEN2APH1B | |
| SCHEMBL4576421 | 0.90 | CTSK (0.65) | CTSKCTSBCTSSCTSLREN | |
| SCHEMBL16984912 | 0.90 | CTSK (0.65) | CTSKCTSBCTSSCTSLREN | |
| SCHEMBL25977611 | 0.90 | CTSK (0.65) | CTSKCTSBCTSSCTSLREN | |
| SCHEMBL14493051 | 0.89 | CTSK (0.64) | CTSKCTSBCTSSCTSLREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112812149-B | Amino acid derivative, preparation method and application thereof, anti-tumor micelle and preparation method thereof | 首都医科大学 | 2022-04-29 | — | — | CN | claimed |
| US-20230270889-A1 | Fluorescently-Traceable Amino Acid Derivative And Preparation Methods And Use Thereof | Capital Medical University (CN) | 2023-08-31 | — | — | US | disclosed |
| CN-113105524-B | Polypeptide derivative copper complex, preparation method and application thereof, and anticancer drug | 首都医科大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-112812149-B | Amino acid derivative, preparation method and application thereof, anti-tumor micelle and preparation method thereof | 首都医科大学 | 2022-04-29 | — | — | CN | disclosed |
| CN-112691081-B | Paclitaxel micelle based on (S) -2-decanoylamino-3- (1-naphthyl) propionyl-leucyl-valine | 首都医科大学 | 2022-04-22 | — | — | CN | disclosed |
| US-20210363119-A1 | PROTEASOME INHIBITORS | NEW MEXICO TECH UNIVERSITY RESEARCH PARK CORPORATION | 2021-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363119-A1 | PROTEASOME INHIBITORS | TP53, CDKN1A, PSME1 | CTSK 646/4885CTSB 975/4885PSEN1 1359/4885 |
| US-20230270889-A1 | Fluorescently-Traceable Amino Acid Derivative And Preparation Methods And Use Thereof | SLC7A5, BCAT2, BCAT1 | CTSK 2777/4885CTSB 3100/4885PSEN1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.